Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by-nc (c) Favà, Àlex et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172072

Treatment of multiple myeloma with renal involvement: the nephrologist's view

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients with MM develop dialysis-dependent acute kidney injury related to increased free light chain (FLC) production by a plasma cell clone. Myeloma cast nephropathy (MCN) is the most prevalent pathologic diagnosis associated with renal injury, followed by light chain deposition disease and light chain amyloidosis. Several FLC removal techniques have been explored to improve kidney disease in MM but their impact on renal clinical outcomes remains unclear. According to the evidence, high cut-off haemodialysis should be restricted to MM patients on chemotherapy with histological diagnosis of MCN and haemodialysis requirements. From our perspective, more efforts are needed to improve kidney outcomes in patients with MM and renal failure.

Matèries (anglès)

Citació

Citació

FAVÀ BUCH, Alexandre, FULLADOSA, Xavier, MONTERO PÉREZ, Núria, DRAIBE, Juliana, TORRAS AMBRÒS, Joan, GOMÀ, Montse, CRUZADO, Josep ma.. Treatment of multiple myeloma with renal involvement: the nephrologist's view. _Clinical Kidney Journal_. 2018. Vol. 11, núm. 6, pàgs. 777-785. [consulta: 15 de gener de 2026]. ISSN: 2048-8505. [Disponible a: https://hdl.handle.net/2445/172072]

Exportar metadades

JSON - METS

Compartir registre